[Experience of using interferon Β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center].

@article{Borets2015ExperienceOU,
  title={[Experience of using interferon Β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center].},
  author={O. G. Borets and M. V. Davydovskaya and T. L. Demina and N Yu Lashch and Natalia Fyodorovna Popova and E. V. Popova and N. V. Khachanova and M V Khasayeva and Sergei Gennadievich Shchur and A. N. Boyko},
  journal={Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova},
  year={2015},
  volume={115 2 Pt 2},
  pages={
          51-56
        }
}
OBJECTIVE To study the efficacy and tolerability of generics (interferon beta-1a biosimilans) cinnovex for intramascular introduction and genfaxon-44 for subcutaneous injections in multiple sclerosis (MS). MATERIAL AND METHODS One hundred patients were treated with cinnovex and 104 patients were treated with genfaxon-44 during one year. Patient's status was assessed using clinical approach, psychometric scales and MRI. RESULTS AND CONCLUSION The high percentage of withdrawal of treatment… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…